Inclusion Criteria
Patients must have:
- HIV positivity.
- No active opportunistic infection within the past 30 days, other than superficial candidiasis of the oral cavity or vagina.
- Body surface area at least 1.0 sqm.
- Consent of parent or guardian.
Prior Medication:
Allowed:
- Aerosolized pentamidine.
- Topical antifungals.
- TMP / SMX.
- AZT.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Significant hepatic disease including HBsAg or hepatitis C positivity.
- Significant neurologic disease such as loss of intellectual ability, motor deficits, or seizure disorder.
- Significant cardiac disease including dysrhythmia or cardiomyopathy.
- Significant medical condition or laboratory abnormality that may pose additional risk to patient on study or confound the results.
- Has a social situation that may interfere with study participation.
Concurrent Medication:
Excluded:
Patients with the following prior conditions are excluded:
- History of serious allergic drug reactions.
- History of significant cardiac disease.
- Participation on another clinical trial within the past 4 weeks.
- Donated blood within the past 4 weeks.
Prior Medication:
Excluded within the past 4 weeks:
- Hematopoietic growth factors.
Excluded within the past 2 weeks:
- Antiretroviral agent other than zidovudine.
- Oral contraceptives.
- Prophylaxis for opportunistic infections, other than aerosolized pentamidine, topical antifungals, and TMP/SMX.
- Any other medication unless approved by Merck clinical monitor. Current illicit drug use.